Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotech company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in June 2025:

• Jefferies Global Healthcare Conference on June 4 in New York - Management will conduct one-on-one meetings and a fireside chat at 2:35 pm ET
• Goldman Sachs Global Healthcare Conference on June 11 in Miami - Including one-on-one meetings and a fireside chat at 2:00 pm ET
• Citi European Healthcare Conference on June 17 in London - Management will participate in one-on-one meetings

News Market Reaction

-3.94%

1 alert

-3.94% News Effect

On the day this news was published, ZYME declined 3.94%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:

• Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on June 4 at 2:35 pm Eastern Time (ET) in New York, NY.
• Goldman Sachs Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on June 11 at 2:00 pm ET in Miami, FL.
• Citi European Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 17 in London, UK.
  

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

What investor conferences will Zymeworks (ZYME) attend in June 2025?

Zymeworks will attend three conferences: Jefferies Global Healthcare Conference (June 4, New York), Goldman Sachs Global Healthcare Conference (June 11, Miami), and Citi European Healthcare Conference (June 17, London).

What is Zymeworks' (ZYME) main business focus?

Zymeworks is a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease.

When and where will Zymeworks (ZYME) present at the Jefferies Healthcare Conference?

Zymeworks will participate in one-on-one meetings and a fireside chat at the Jefferies Global Healthcare Conference on June 4 at 2:35 pm ET in New York.

Will Zymeworks (ZYME) management conduct fireside chats at all three conferences?

No, Zymeworks will conduct fireside chats at two conferences: Jefferies and Goldman Sachs. At the Citi European Healthcare Conference, they will only participate in one-on-one meetings.